A pharmacogenomic test that identifies medications with significant gene-drug interactions to inform prescribing
Access impacts prescribing decisions: Patients whose providers did NOT have access to GeneSight ~two times more likely to receive antidepressant with significant GDIs1
GeneSight helped improve outcomes in multiple clinical studies: Level 1 evidence demonstrates 49% relative improvement in depression remission2
Find more Myriad info as well as links to National Institutes of Health mental health and pharmacogenomics resources.